Approval · Notice of Compliance 36331 · 2025
RYBREVANT: Notice of Compliance 36331
Issued November 4, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36331
- Date
- November 4, 2025
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYBREVANT | Not yet assigned | — |
Medicinal ingredients
- AMIVANTAMAB 350 MG per 7ML